|
|
||||||||
Department of Radiology, Division of Radiation Research, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103
Correspondence: For reprints contact: Roger W. Howell, PhD, Department of Radiology, MSB F-451, UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103.
ABSTRACT
One of the most promising areas for cancer therapy with administered radiopharmaceuticals is the treatment of very small tumors and micrometastases. Small tumors and micrometastases, however, may be rapidly growing at the time of treatment, resulting in a substantial change in mass during the period of irradiation. In this work, the formalism required to calculate the average absorbed dose to rapidly growing tumors is developed and applied to an in vitro tumor model. Further application to in vivo human myeloma tumors reveals that tumor growth may have a significant effect on the average dose delivered to the tumor from incorporated radionuclides. These considerations may assist in establishing dose-response relationships necessary for radiopharmaceutical cancer therapy.
This article has been cited by other articles:
![]() |
C. Hindorf, O. Linden, L. Stenberg, J. Tennvall, and S.-E. Strand Change in Tumor-absorbed Dose due to Decrease in Mass during Fractionated Radioimmunotherapy in Lymphoma Patients Clin. Cancer Res., September 1, 2003; 9(10): 4003S - 4006. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Thakur, R. Coss, R. Howell, D. Vassileva-Belnikolovska, J. Liu, S. P. Rao, G. Spana, P. Wachsberger, and D. L. Leeper Role of Lipid-Soluble Complexes in Targeted Tumor Therapy J. Nucl. Med., August 1, 2003; 44(8): 1293 - 1300. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |